GENFIT Publishes Insights on 2025 Extra-Financial Performance
GENFIT (NASDAQ and Euronext: GNFT), a biopharmaceutical company dedicated to patients with rare and life-threatening liver diseases, has made an exciting announcement about the publication of its 2025 Extra-Financial Performance Report, reflecting its fiscal year actions and impacts.
Responding to Stakeholder Interests
In response to growing interest from stakeholders, including shareholders, analysts, and potential employees, GENFIT has been presenting detailed reports on its sustainability efforts since 2022. The latest report, which focuses on fiscal year 2024, provides valuable insights into the company's commitment to environmental, social, and governance (ESG) practices. It's a positive step for deeper corporate transparency and stakeholder engagement.
CEO's Vision for Sustainable Development
Pascal Prigent, the CEO of GENFIT, highlighted the company’s commitment to sustainable development. He noted, "Our corporate culture is rooted in sustainability, guiding our strategy since GENFIT's inception. The ESG Committee was established in 2021, streamlining our approach with clear objectives and concrete actions. By prioritizing what matters to us and observing regulatory updates, we're not only managing risks but also harnessing opportunities for growth. This approach fosters trust among patients, investors, and regulators alike."
Commitment to Social Responsibility
Throughout 2024, GENFIT has remained dedicated to enhancing its social and environmental responsibility. The ESG Committee’s roadmap has led to significant engagement with patients through awareness initiatives that educate the public on ACLF, supported by collaboration with international experts.
Catalyzing Positive Change
The organization's efforts included a comprehensive evaluation of gender equality in the workplace and the continuation of successful initiatives from previous years. Despite regulatory changes, GENFIT is committed to aligning with European standards through a voluntary approach consistent with its corporate values.
Feedback and Future Directions
Building on feedback and past experiences, GENFIT's 2025 roadmap aims to further its journey toward sustainability and corporate responsibility. The organization understands that its long-term financial success is correlated with its social impact and governance practices.
Thoughts from Partners and Patients
Caroline Bendavid from HOMA Capital noted, "At HOMA Capital, we respect the social responsibility of companies we invest in, and GENFIT's initiatives reflect this commitment. Their preventive health campaigns, like those for breast cancer, serve as a good model for action within organizations."
Jon Potter, an ACLF patient, shared his enthusiasm about GENFIT's clinical trials aimed at developing treatments for severe liver conditions: "Being part of GENFIT's ACLF Patient Advocacy Council brings real hope not only to patients but also their families and friends. It's heartening to witness GENFIT's progress in making a positive difference."
About GENFIT's Corporate Social Responsibility
GENFIT's drive for corporate social responsibility is reflective of its desire to act as a socially accountable organization. As a biopharmaceutical entity, their mission is to develop innovative therapies that cater to pressing societal healthcare needs, particularly targeting liver diseases that pose significant challenges.
Aligning with Sustainable Development Goals
Their commitment aligns with the United Nations' Sustainable Development Goals, emphasizing the connection between the company’s financial performance and its extra-financial outcomes. This focus enables them to provide substantial long-term value to patients, healthcare systems, and shareholders.
GENFIT's Ongoing Innovations and Future Prospects
Headquartered in Lille, France, GENFIT stands out in liver disease research with a growing R&D portfolio that includes multiple programs at different development stages. The company’s strong pipeline showcases five assets dedicated to treating ACLF, leveraging various action mechanisms across diverse administration routes.
A Broader Vision in Biopharmaceuticals
Beyond its focus on liver diseases, GENFIT is working on other critical health conditions, demonstrating a robust research ethos. Their successful development of Iqirvo® (elafibranor) set a precedent for expedited approvals in multiple regulatory markets, which speaks volumes about their capabilities in advancing cutting-edge therapy solutions.
Frequently Asked Questions
What is GENFIT's main focus in research?
GENFIT primarily focuses on rare and life-threatening liver diseases, with a significant emphasis on Acute-on-Chronic Liver Failure (ACLF).
How does GENFIT engage with its stakeholders?
GENFIT engages with stakeholders through comprehensive CSR reports and various initiatives that promote transparency and accountability.
What role does the ESG Committee play in GENFIT?
The ESG Committee establishes structured roadmaps for sustainability initiatives, sets clear objectives, and monitors related indicators.
What is the significance of the 2025 Extra-Financial Report?
The 2025 Extra-Financial Report outlines GENFIT's progress in sustainability and corporate social responsibility, reflecting its commitment to social and environmental responsibility.
How can one contact GENFIT for investor inquiries?
Investors can reach GENFIT at +33 3 20 16 40 00 or via email at investors@genfit.com.
